NRx Pharmaceuticals, Inc. (NRXP) |
1.23 -0.02 (-1.6%)
|
01-27 16:00 |
Open: |
1.22 |
Pre. Close: |
1.25 |
High:
|
1.26 |
Low:
|
1.1801 |
Volume:
|
246,692 |
Market Cap:
|
83(M) |
|
|
Technical analysis |
as of: 2023-01-27 4:46:39 PM |
Overall:
|
|
Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
Target: |
Six months: 1.64 One year: 1.92 |
Support: |
Support1: 1.17 Support2: 1.02 |
Resistance: |
Resistance1: 1.4 Resistance2: 1.64 |
Pivot: |
1.26  |
Moving Average: |
MA(5): 1.25 MA(20): 1.23 
MA(100): 0.99 MA(250): 1.3  |
MACD: |
MACD(12,26): 0 Signal(9): 0  |
Stochastic oscillator: |
%K(14,3): 49.4 %D(3): 53.8  |
RSI: |
RSI(14): 50.2  |
52-week: |
High: 3.53 Low: 0.49 |
Average Vol(K): |
3-Month: 393 (K) 10-Days: 305 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NRXP ] has closed above bottom band by 33.7%. Bollinger Bands are 20.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
1.26 - 1.27 |
1.27 - 1.28 |
Low:
|
1.16 - 1.17 |
1.17 - 1.18 |
Close:
|
1.22 - 1.23 |
1.23 - 1.24 |
|
Company Description |
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware. |
Headline News |
Thu, 19 Jan 2023 NRXP stock gains on FDA comments regarding lead asset ... - Seeking Alpha
Thu, 05 Jan 2023 NRx Pharmaceuticals: A Speculative, Binary Play (NASDAQ:NRXP) - Seeking Alpha
Tue, 03 Jan 2023 XPEV, LI and BILI are among pre market gainers - Seeking Alpha
Tue, 03 Jan 2023 Health Care Sector Update for 01/03/2023: XLV, VHT, TXMD, SY ... - Nasdaq
Tue, 03 Jan 2023 NRXP stock gains as Phase 3 trial for bipolar candidate starts ... - Seeking Alpha
Mon, 05 Dec 2022 NRx Pharmaceuticals Announces the Appointment of Carrie M ... - PR Newswire
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Underperform |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Underperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. |
68 (M) |
Shares Float |
40 (M) |
% Held by Insiders
|
44.1 (%) |
% Held by Institutions
|
7.1 (%) |
Shares Short
|
1,520 (K) |
Shares Short P.Month
|
1,310 (K) |
Stock Financials |
EPS
|
-6.25 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
0.25 |
Profit Margin (%)
|
0 |
Operating Margin (%)
|
0 |
Return on Assets (ttm)
|
-156 |
Return on Equity (ttm)
|
-474.4 |
Qtrly Rev. Growth
|
0 |
Gross Profit (p.s.)
|
0 |
Sales Per Share
|
0 |
EBITDA (p.s.)
|
-1.3 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
-43 (M) |
Levered Free Cash Flow
|
-79 (M) |
Stock Valuations |
PE Ratio
|
-0.2 |
PEG Ratio
|
0 |
Price to Book value
|
4.92 |
Price to Sales
|
0 |
Price to Cash Flow
|
-1.95 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|